联合68Ga-前列腺特异性膜抗原-HBED-CC同步PET与多参数MRI及临床参数提高原发性前列腺癌诊断
回顾性纳入82例男性(63个恶性、21个良性前列腺病灶),评估68Ga-PSMA PET与多参数MRI及临床参数的诊断效能。PSMA最大标准化摄取值在Gleason评分7、8、9分肿瘤间有显著差异,7分最低、9分最高。联合ROC分析显示PSA、直肠指检、多参数MRI与差分PSMA摄取的联合AUC为0.94±0.03,高于各自单独AUC(0.77、0.70、0.82、0.88)。
要点
- Gleason评分7、8、9分肿瘤的PSMA最大标准化摄取值有显著差异,7分最低、9分最高。
- 联合PSA、直肠指检、多参数MRI与差分PSMA摄取的AUC为0.94±0.03,高于各单独参数。
- 恶性前列腺病灶早期相与延迟相PSMA摄取有显著差异(p<0.01)。
核心结论
- 68Ga-PSMA PET联合多参数MRI对前列腺癌诊断的准确率高于单独多参数MRI、单独PET或单独临床因素(如直肠指检或PSA水平),联合进一步改善前列腺病灶的表征。
研究设计与样本
- 回顾性研究,纳入82例男性(63个恶性、21个良性组织学证实前列腺病灶),均行全身68Ga-PSMA PET/MRI同步采集并专用多参数MRI,采用PI-RADS v2评估癌症可能性。
关键影像表现/征象
- PSMA最大标准化摄取值在Gleason评分7、8、9分肿瘤间有显著差异,7分肿瘤摄取最低、9分肿瘤摄取最高。
- 恶性前列腺病灶早期相与延迟相PSMA摄取有显著差异(p<0.01)。
- 延迟相与差分PSMA摄取均与PI-RADS分类显著相关(p<0.01和<0.01)。
- 延迟相与差分PSMA摄取均与直肠指检所见显著相关(p=0.01和<0.01)。
- 延迟相与差分PSMA摄取均与Gleason评分显著相关(p=0.05和<0.05),与PSA水平亦显著相关(两者p=0.01)。
诊断标准与关键数值
- 联合ROC分析PSA水平、直肠指检所见、多参数MRI与差分PSMA摄取表征前列腺病灶的AUC为0.94±0.03。
- 单独PSA水平的AUC为0.77。
- 单独直肠指检所见的AUC为0.70。
- 单独多参数MRI的AUC为0.82。
- 单独差分PSMA摄取的AUC为0.88。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: The current study was designed to test the diagnostic performance of 68Ga-prostate-specific membrane antigen (PSMA) PET and multiparametric MRI along with clinical parameters in the characterization of prostatic lesions.
MATERIALS AND METHODS: Eighty-two men with 63 malignant and 21 benign histologically proven prostate lesions who underwent complete clinical workup were included in this retrospective study. All patients underwent simultaneous whole-body 68Ga-PSMA PET/MRI with dedicated multiparametric MRI. Prostate Imaging-Reporting and Data System (PI-RADS) version 2 assessment was used for predicting the likelihood of cancer. Uptake of 68Ga-PSMA was recorded by adopting the copy-and-paste function of ROIs defined on MR images. ROC and combined ROC analyses were performed to test the diagnostic accuracy of individual and combined parameters. Spearman analysis was used to assess the correlations.
RESULTS: PSMA uptake (maximum standardized uptake value) was significantly different among tumors with Gleason scores of 7, 8, and 9, with the lowest uptake in tumors with a score of 7 and the highest uptake in tumors with a score of 9. There was a significant difference between early- and delayed-phase PSMA uptake in malignant prostatic lesions (p < 0.01). Significant correlations were observed between delayed and differential PSMA uptake and PI-RADS category (p < 0.01 and < 0.01, respectively), digital rectal examination findings (p = 0.01 and < 0.01, respectively), Gleason score (p = 0.05 and < 0.05, respectively), and prostate-specific antigen levels (p = 0.01 for both). Combined ROC analysis of prostate-specific antigen levels, digital rectal examination findings, multiparametric MRI, and differential PSMA uptake were able to characterize prostatic lesions with a mean (± SD) AUC of 0.94 ± 0.03, compared with their individual AUCs of 0.77, 0.70, 0.82, and 0.88.
CONCLUSION: Gallium-68-PSMA PET combined with multiparametric MRI showed high diagnostic accuracy for prostate cancer diagnosis compared with either multiparametric MRI or PET alone or with clinical factors (e.g., digital rectal examination or prostate-specific antigen level) alone, and the combination further improves characterization of prostatic lesions.
引用
- Jena A, Taneja R, Taneja S, et al. Improving Diagnosis of Primary Prostate Cancer With Combined 68Ga-Prostate-Specific Membrane Antigen-HBED-CC Simultaneous PET and Multiparametric MRI and Clinical Parameters. AJR Am J Roentgenol. 2018. PMID: 30300002. doi:10.2214/AJR.18.19585
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。